Summary
PepsiCo, Inc. (PEP) announced a significant addition to its Board of Directors with the election of Dr. David C. Page, effective November 20, 2014. Dr. Page, a distinguished figure in biomedical research and a professor at MIT, will serve as an independent director and join the Audit Committee. This appointment brings valuable scientific and research expertise to the board's oversight functions, particularly concerning financial reporting and internal controls. Investors can view this as a move to strengthen board governance and leverage specialized knowledge in areas relevant to the company's operations and long-term strategy. The compensation package for Dr. Page aligns with PepsiCo's non-employee director compensation program, including an initial stock award and phantom stock units, indicating a commitment to aligning director interests with those of shareholders. The filing also confirms the company's adherence to regulatory reporting requirements.
Key Highlights
- 1PepsiCo elected Dr. David C. Page as an independent director to its Board, effective November 20, 2014.
- 2Dr. Page will serve on the Board's Audit Committee, enhancing oversight of financial reporting and controls.
- 3Dr. Page's background includes leadership roles at the Whitehead Institute for Biomedical Research and professorships at MIT.
- 4The appointment aims to bring specialized expertise in scientific and research fields to the Board.
- 5Dr. Page will receive an initial stock award of 1,000 shares of PepsiCo Common Stock.
- 6He will also receive a prorated annual equity award in the form of phantom stock units.
- 7Dr. Page is entitled to an annual cash retainer of $55,000 per semi-annual payment.